Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States
This cross-sectional online survey (n=228) examined the effects of psychedelic use on healthcare providers who treat psychiatric disorders with medications. The study found that psychedelic use was associated with improvements in depression, anxiety, well-being, and resilience, and a decrease in reported suicidality. A factor analysis indicated that a combination of mystical, interpersonal, and personal experiences predicted these improvements. The preferred psychedelic agent did not influence outcomes, and frequency of use showed varied effect sizes. While 13.2% (n=30) reported at least one harm from psychedelic use, the results suggest potential benefits for healthcare providers, consistent with findings from other studies on the general population.
Authors
- Charles Raison
- Brian Barnett
Published
Abstract
Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a large cross-sectional online survey consisting of participants with at least one lifetime psychedelic use sought to examine how use affects health care providers who treat psychiatric disorders with medications. In total, 228 respondents retrospectively completed measures of depression, anxiety, and well-being before and after psychedelic exposure. They also reported lifetime use, harms attributed to use, and preferred psychedelic agent. Psychedelic use was associated with improvements in depression, anxiety, and well-being. Reported suicidality decreased and resilience increased. A factor analysis suggested that a cluster of mystical, interpersonal, and personal items predicted improvement in depression, anxiety, well-being, suicidality, and resilience. Preferred psychedelic agent did not affect outcomes. Frequency of use was not associated with outcomes although differences in effect sizes were seen. Harm reported was consistent with the general population, with 13.2% (n = 30) reporting at least one harm. Pre-exposure alcohol use, aggressive impulses, and desire to die by suicide improved most often while marijuana use most often worsened or did not change. These results are consistent with clinical trials and naturalistic studies examining psychedelic use in the general population and suggest that health care providers who treat psychiatric disorders with medications may benefit from psychedelic use, although some harm was reported. Given the current mental health crisis among health care providers, further research is warranted to examine whether interventions utilizing psychedelics could improve well-being and effectiveness of health care providers while decreasing adverse mental health outcomes associated with working in health care.
Research Summary of 'Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States'
Introduction
Herrmann and colleagues frame their study within a recognised mental health crisis among health care workers, noting high rates of depression, anxiety, burnout and suicide that have been exacerbated by the COVID-19 pandemic. Earlier research and recent clinical trials suggest that psychedelic-assisted therapies and naturalistic psychedelic use can reduce symptoms of depression and anxiety, lower suicidality, and improve aspects of well-being and resilience in general populations. The authors highlight that little is known about how naturalistic psychedelic use affects clinicians who prescribe psychiatric medications, partly because of concerns about professional and legal repercussions that discourage disclosure. This paper reports a secondary analysis of data from the larger Psychedelics and Wellness Study (PAWS). The specific aim was to examine retrospective self-reported changes in depression, anxiety, emotional well-being, resilience and suicidal ideation among prescribers of psychiatric medication who have used psychedelics at least once. Secondary aims included exploring associations with lifetime use patterns, preferred psychedelic agent, and harms attributed to use. The authors hypothesised that respondents would generally report improvements on the assessed measures and that harms would be less common.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Topics
- Authors
- APA Citation
Herrmann, Z., Levin, A. W., Cole, S. P., Slabaugh, S., Barnett, B., Penn, A., Jain, R., Raison, C., Rajanna, B., & Jain, S. (2023). Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Psychedelic Medicine, 1(3), 139-149. https://doi.org/10.1089/psymed.2023.0030
References (31)
Papers cited by this study that are also in Blossom
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Holze, F., Gasser, P., Müller, F. et al. · Biological Psychiatry (2023)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Show all 31 referencesShow fewer
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Raison, C. L., Jain, R., Jain, S. et al. · Frontiers in Psychiatry (2022)
Nygart, V., Pommerencke, L. M., Haijen, E. et al. · Journal of Psychopharmacology (2022)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Lawn, W., Hallak, J. E., Crippa, J. A. et al. · Scientific Reports (2017)
Di Virgilio, A., Di Virgilio, V., Minerbi, A. et al. · MedRvix (2023)
Mans, K., Kettner, H., Erritzoe, D. et al. · Frontiers in Psychiatry (2021)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Cohen, S. · Journal of Nervous and Mental Disease (1980)
DellaCrosse, M., Pleet, M. M., Morton, E. et al. · PLOS ONE (2022)
Hendricks, P. S. · International Review of Psychiatry (2018)
Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Zeifman, R. J., Wagner, A. C., Monson, C. M. et al. · Journal of Affective Disorders (2023)
Aday, J. S., Skiles, Z., Eaton, N. et al. · Psychedelic Medicine (2023)
Nielson, E. M., Guss, J. · Journal of Psychedelic Studies (2018)
Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)
Page, L., Rehman, A., Syed, H. et al. · Frontiers in Psychiatry (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.